Latest News & PR
In Chromatography, Nanologica aims to make insulin and other diabetes drugs available to more patients in need by lowering the manufacturing costs. Thanks to Nanologica’s proprietary silica manufacturing process, the company can provide products with high performance as well as chemical and mechanical stability. This results in lower production costs for the company’s customers as the products last longer and make the purification process more efficient.
Nanologica’s purification media NLAB Saga® has been developed to meet the requirements of industrial purification, primarily to suit purification processes for insulin and other peptides.
Nanologica focuses its Drug Development business on inhaled drugs and respiratory diseases. The company’s platform technology is being developed both in internal projects and together with pharmaceutical partners, to reformulate active pharmaceutical ingredients, APIs, that in current formulations do not provide optimal treatment for patients.
By reformulating clinically proven APIs into inhaled formulations, Nanologica may significantly improve patients’ quality of life and/or enable local treatment to the lung where today only systemic treatment is available. The goal is to provide a platform technology that enables improved or completely new treatments for patients with severe lung diseases.
News & PRESS RELEASES
Nanologica’s Interim Report Jan-Sep 2022
Nanologica AB’s Interim Report Jan-Sep 2022 The auditor’s report Q3 2022 (Swedish) Report presentation Q3 2022 FINANCIAL SUMMARY Net sales for the third quarter amounted to TSEK 401 (2,119) and for the nine-month period to TSEK 881 (12,238) The operating result for the quarter amounted to TSEK -9,610 (-11,718) and for the nine-month period
5 Quick Questions with Katarina Alenäs
Katarina Alenäs, SVP Chromatography Nanologica AB Who is Katarina Alenäs? I have a M.Sc. in Chemical Engineering and a B.Sc. in Pharmaceutical Sciences and have spent most of my professional career within chromatography which is an area very close to my heart. Before joining Nanologica, I was the Country General Manager at Agilent Technologies Sweden,
Nanologica is a public company listed for trade on Nasdaq Stockholm Main Market. For information regarding financial reports, press releases, presentations and share holder information, please visit our investor relations section.
Presentation of Nanologica
Company presentation made by CEO Andreas Bhagwani on August 24, 2022.
For more videos about the company as well as video presentations of interim reports, please refer to Investor Relations.